Cellular Technology Limited — CTL

Cellular Technology Limited (CTL) has been pioneering the ELISPOT technology for immune monitoring, with a mission of “Elevating ELISPOT to an Exact Science”. Serving over 2,000 clients from academia and industry worldwide, CTL offers unparalleled expertise in immune monitoring. Their offerings include contract laboratory services with an emphasis on T and B cells in a CLIA-certified, GLP-compliant laboratory, as well as comprehensive solutions for sample processing and all-around ELISPOT services including protocols, reagents, reference samples, and immunoSpot® kits. Additionally, they provide consultation, hands-on workshop training, and analyzers for automated and objective ELISPOT data analysis. Founded in 1998 and headquartered in the United States, CTL operates in the biotechnology and information technology industries. While the last investment details are not available, the company has positioned itself as a crucial player in the field of immune monitoring, catering to a global clientele with innovative products and solutions. Overall, CTL's unique blend of technology and expertise sets it apart in the rapidly evolving domain of immune monitoring.